Trials / Recruiting
RecruitingNCT06444399
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | 6 mg administered orally twice daily for 24 weeks. |
Timeline
- Start date
- 2024-07-29
- Primary completion
- 2025-09-02
- Completion
- 2026-07-01
- First posted
- 2024-06-05
- Last updated
- 2026-02-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06444399. Inclusion in this directory is not an endorsement.